Detail akcie Milestone Pharma Rg online

Business Summary: Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Milestone Pharmaceuticals Inc revenues was not reported. Net loss increased from $10.4M to $20.8M. Higher net loss reflects Commercial activities increase from $2.8M to $10.2M (expense), General and administrative increase of 46% to $4.4M (expense), Research and development increase of 41% to $4.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.21 to -$0.39.